However, the safety and efficacy of sitagliptin for these off-label uses have not been conclusively established, and further research is needed to determine its role in these conditions
Additional randomized, controlled trials that follow people over time are needed to confirm these findings, but these results are promising, since people with diabetes are at increased risk for developing epilepsy later in life, said study author Edy Kornelius, MD, PhD, of Chung Shan Medical University in Taichung, Taiwan
The status of a currently ongoing trial (NCT 00098852) with rosiglitazone is not known
Unlike oral supplements, injections bypass the digestive system, allowing nutrients to absorb more efficiently
Frequently Asked Questions What is the Wolverine peptide and how does it relate to BPC-157 & TB-500 Blend
After that, discard any leftover doses